Volume : 10, Issue : 04, April – 2023
Title:
17.A COMPREHENSIVE REVIEW ON FECAL MICROBIOTA TRANSPLANTATION THERAPY
Authors :
B. Purna Chandu*, E. Jagadish Kumar
Abstract :
Over a decade fecal microbiota transplantation emerged as the best treatment approach in the therapy of dysbiosis-related diseases by improving or restoring the composition of the recipient’s gut microbiota. FMT is highly recommended and effective in case of recurrent or refractory Clostridioides difficile infection (CDI) WITH 90% of cure rates. Despite the anticipated therapeutic advantages of FMT, the precise mechanism of action of FMT is not well understood. FDA released a safety alert regarding the potential life-threatening infections that may occur after a fecal microbiota transplant. Several RCT and clinical trials are performing on the FMT to understand the efficacy and safety in various other gut-related disorders. In this Review, we emphasized the mechanism of action, indications and contraindications, complications, and management of FMT in other diseases.
Keywords: Fecal Microbiota Transplantation, Clostridium Infections, Gastrointestinal diseases
Cite This Article:
Please cite this article in press B. Purna Chandu et al, A Comprehensive Review On Fecal Microbiota Transplantation Therapy., Indo Am. J. P. Sci, 2023; 10 (04).
Number of Downloads : 10
References:
1. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc [Internet]. 2013 Aug [cited 2023 Feb 10];78(2):240–9. Available from: https://pubmed.ncbi.nlm.nih.gov/23642791/
2. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol [Internet]. 2012 Nov [cited 2023 Feb 10];107(11):1755. Available from: https://pubmed.ncbi.nlm.nih.gov/23160295/
3. Medicine RLP in B and, 2001 undefined. More on merde. muse.jhu.edu [Internet]. 2001 [cited 2023 Feb 10]; Available from: https://muse.jhu.edu/pub/1/article/26083/summary
4. Smits LP, Bouter KEC, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology [Internet]. 2013 [cited 2023 Feb 10];145(5):946–53. Available from: https://pubmed.ncbi.nlm.nih.gov/24018052/
5. SH C, DN G, S J, CP K, VG L, LC M, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol [Internet]. 2010 [cited 2023 Feb 10];31(5):426–7. Available from: https://pubmed.ncbi.nlm.nih.gov/20307191/
6. Thabit AK, Alsolami MH, Baghlaf NA, Alsharekh RM, Almazmumi HA, Alselami AS, et al. Comparison of three current Clostridioides difficile infection guidelines: IDSA/SHEA, ESCMID, and ACG guidelines. Infection [Internet]. 2019 Dec 1 [cited 2023 Feb 10];47(6):899–909. Available from: https://pubmed.ncbi.nlm.nih.gov/31428991/
7. DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, et al. Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant . New England Journal of Medicine. 2019 Nov 21;381(21):2043–50.
8. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010 464:7285 [Internet]. 2010 [cited 2023 Feb 10];464(7285):59–65. Available from: https://www.nature.com/articles/nature08821
9. Sender R, Fuchs S, Milo R. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. Cell [Internet]. 2016 Jan 28 [cited 2023 Feb 10];164(3):337–40. Available from: https://pubmed.ncbi.nlm.nih.gov/26824647/
10. Soo WT, Bryant R v., Costello SP. Faecal microbiota transplantation: Indications, evidence and safety. Aust Prescr. 2020 Apr 1;43(2):36–8.
11. Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Clinical Application and Potential of Fecal Microbiota Transplantation. Annu Rev Med [Internet]. 2019 Jan 27 [cited 2023 Feb 10];70:335–51. Available from: https://pubmed.ncbi.nlm.nih.gov/30403550/
12. Trubiano JA, Cheng AC, Korman TM, Roder C, Campbell A, May MLA, et al. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J [Internet]. 2016 Apr 1 [cited 2023 Feb 10];46(4):479–93. Available from: https://pubmed.ncbi.nlm.nih.gov/27062204/
13. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol [Internet]. 2010 May [cited 2023 Feb 10];44(5):354–60. Available from: https://pubmed.ncbi.nlm.nih.gov/20048681/
14. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol [Internet]. 2012 May [cited 2023 Feb 10];107(5):761–7. Available from: https://pubmed.ncbi.nlm.nih.gov/22290405/
15. Wang JW, Kuo CH, Kuo FC, Wang YK, Hsu WH, Yu FJ, et al. Fecal microbiota transplantation: Review and update. Vol. 118, Journal of the Formosan Medical Association. Elsevier B.V.; 2019. p. S23–31.
16. Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies | FDA [Internet]. [cited 2023 Feb 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota
17. Smith E, Duarte-Chavez R, Samia H, Knight P, Tolentino J, Wojda T, et al. Fecal microbiota transplantation: Safe, simple, and effective. Int J Acad Med. 2018;4(2):142.
18. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut [Internet]. 2017 Apr 1 [cited 2023 Feb 10];66(4):569–80. Available from: https://pubmed.ncbi.nlm.nih.gov/28087657/
19. Bakken JS, Borody T, Brandt LJ, Brill J v., Demarco DC, Franzos MA, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol [Internet]. 2011 Dec [cited 2023 Feb 10];9(12):1044–9. Available from: https://pubmed.ncbi.nlm.nih.gov/21871249/
20. Paramsothy S, Borody TJ, Lin E, Finlayson S, Walsh AJ, Samuel D, et al. Donor Recruitment for Fecal Microbiota Transplantation. Inflamm Bowel Dis [Internet]. 2015 May 19 [cited 2023 Feb 10];21(7):1600–6. Available from: https://pubmed.ncbi.nlm.nih.gov/26070003/
21. Vindigni SM, Surawicz CM. Fecal Microbiota Transplantation. Gastroenterol Clin North Am [Internet]. 2017 Mar 1 [cited 2023 Feb 10];46(1):171–85. Available from: https://pubmed.ncbi.nlm.nih.gov/28164849/
22. Wang Y, Zhang S, Borody TJ, Zhang F. Encyclopedia of fecal microbiota transplantation: A review of effectiveness in the treatment of 85 diseases. Vol. 135, Chinese Medical Journal. Lippincott Williams and Wilkins; 2022. p. 1927–39.
23. Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms | FDA [Internet]. [cited 2023 Feb 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse-events-likely